Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Conivaptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 known ✓ | P30518 | 16/20 | 0.75 |
| ▸ | AVPR1A known ✓ | P37288 | 13/20 | 0.75 |
| ▸ | OXTR | P30559 | 1/20 | 0.59 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Conivaptan SCHEMBL29406590 | 1.00 | AVPR2 (0.75) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL387232 | 0.99 | AVPR2 (0.74) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6987926 | 0.95 | AVPR2 (0.68) | AVPR2AVPR1AOXTRAVPR1B | |
| Hydrochloric Acid SCHEMBL6988764 | 0.94 | AVPR2 (0.67) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL13696611 | 0.91 | AVPR2 (0.63) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL5516287 | 0.91 | AVPR2 (0.63) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6986559 | 0.91 | AVPR1A (0.62) | AVPR2AVPR1AOXTR | |
| Hydrochloric Acid SCHEMBL6993820 | 0.90 | AVPR1A (0.61) | AVPR2AVPR1AOXTR | |
| SCHEMBL6994333 | 0.90 | AVPR2 (0.61) | AVPR2AVPR1AOXTR | |
| SCHEMBL6988740 | 0.89 | AVPR2 (0.65) | AVPR2AVPR1AOXTRAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080199522-A1 | TIMED-RELEASE COMPRESSION-COATED SOLID COMPOSITION FOR ORAL ADMINISTRATION | ASTELLAS PHARMA, INC. (JP) | 2008-08-21 | — | — | US | claimed |
| EP-1008354-B1 | IMMEDIATELY DISINTEGRABLE MEDICINAL COMPOSITIONS | ASTELLAS PHARMA INC (JP) | 2008-06-04 | — | — | EP | claimed |
| US-7189415-B2 | Rapidly disintegrable pharmaceutical composition | ASTELLAS PHARMA INC. (JP) | 2007-03-13 | — | — | US | claimed |
| EP-1759712-A2 | Rapidly disintegrable pharmaceutical composition | Astellas Pharma Inc. (JP) | 2007-03-07 | — | — | EP | claimed |
| US-20070014856-A1 | Rapidly disintegrable pharmaceutical composition | ASTELLAS PHARMA INC. | 2007-01-18 | — | — | US | claimed |
| US-20060292221-A1 | TIMED-RELEASE COMPRESSION-COATED SOLID COMPOSITION FOR ORAL ADMINISTRATION | ASTELLAS PHARMA, INC. (JP) | 2006-12-28 | — | — | US | claimed |
| US-6899899-B2 | Rapidly disintegrable pharmaceutical composition | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-31 | — | — | US | claimed |
| US-20050095289-A1 | Rapidly disintegrable pharmaceutical composition | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2005-05-05 | — | — | US | claimed |
| EP-0709386-B1 | FUSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMA CO LTD (JP) | 2003-05-07 | — | — | EP | claimed |
| EP-1275381-A1 | TIME-RELEASE COATED SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-15 | — | — | EP | claimed |
| US-20030003146-A1 | Rapidly disintegrable pharmaceutical composition | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2003-01-02 | — | — | US | claimed |
| US-20020031547-A1 | IMMEDIATELY DISINTEGRABLE MEDICINAL COMPOSITION | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2002-03-14 | — | — | US | claimed |
| US-20020028240-A1 | Timed-release compression-coated solid composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2002-03-07 | — | — | US | claimed |
| US-6268359-B1 | Preventives or remedies for vision disorders | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-31 | — | — | US | claimed |
| EP-1050308-A1 | PREVENTIVES OR REMEDIES FOR VISION DISORDERS | Senju Pharmaceutical Co., Ltd. (JP) | 2000-11-08 | — | — | EP | claimed |
| EP-1008354-A1 | IMMEDIATELY DISINTEGRABLE MEDICINAL COMPOSITIONS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-06-14 | — | — | EP | claimed |
| EP-0709386-A1 | FUSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-05-01 | — | — | EP | claimed |
| JP-11343240-A | — | — | None | — | — | JP | disclosed |
| JP-H08231403-A | STABLE AQUEOUS SOLUTION CONTAINING ARGININE VASOPRESSIN ANTAGONIST | YAMANOUCHI PHARMACEUT CO LTD | 1996-09-10 | — | — | JP | disclosed |
| EP-0709386-A1 | FUSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199522-A1 | TIMED-RELEASE COMPRESSION-COATED SOLID COMPOSITION FOR ORAL ADMINISTRATION | CRH, HRH2, HES1 | AVPR2 1164/4885AVPR1A 2668/4885OXTR 814/4885 |
| US-20020028240-A1 | Timed-release compression-coated solid composition for oral administration | CRH, HRH2, HES1 | AVPR2 1164/4885AVPR1A 2668/4885OXTR 814/4885 |
| US-20060292221-A1 | TIMED-RELEASE COMPRESSION-COATED SOLID COMPOSITION FOR ORAL ADMINISTRATION | CRH, HRH2, HES1 | AVPR2 1164/4885AVPR1A 2668/4885OXTR 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.